Interleukin 11, Thrombocytopenia, Imatinib in Chronic Myelogenous Leukemia (CML) Patients

PHASE2CompletedINTERVENTIONAL
Enrollment

8

Participants

Timeline

Start Date

October 31, 2005

Primary Completion Date

January 31, 2011

Study Completion Date

January 31, 2011

Conditions
LeukemiaChronic Myelogenous LeukemiaChronic Myeloid Leukemia
Interventions
DRUG

Interleukin-11 (IL-11 or Neumega)

10 mcg/kg under the skin (usually of the arms, legs or abdomen) three times weekly. If the treatment is well tolerated but there is not enough of a platelet improvement, the dose and frequency of injections may be increased.

Trial Locations (1)

77030

UT MD Anderson Cancer Center, Houston

All Listed Sponsors
collaborator

Wyeth is now a wholly owned subsidiary of Pfizer

INDUSTRY

lead

M.D. Anderson Cancer Center

OTHER

NCT00493181 - Interleukin 11, Thrombocytopenia, Imatinib in Chronic Myelogenous Leukemia (CML) Patients | Biotech Hunter | Biotech Hunter